Valeant closes $930 mln sale of iNova to Pacific Equity, Carlyle
Valeant Pharmaceuticals International Inc (TSX, NYSE: VRX) has wrapped up the sale of its iNova Pharmaceuticals affiliate to Australasian private equity firm Pacific Equity Partners and U.S. private equity firm Carlyle Group. The deal, announced in June, reflected a purchase price of US$930 million in cash. Valeant acquired iNova in 2011 from Archer Capital and Ironbridge Capital for about US$623 million. The Laval, Québec-based specialty pharmaceutical company decided to sell the business to pay down debt.
29 September 2017•2 mins read
